| scholarly article | Q13442814 |
| P50 | author | Miranda Grounds | Q63882655 |
| P2093 | author name string | Marta L Fiorotto | |
| Hannah G Radley-Crabb | |||
| P2860 | cites work | A single 30 min treadmill exercise session is suitable for 'proof-of concept studies' in adult mdx mice: a comparison of the early consequences of two different treadmill protocols | Q84748774 |
| Glucocorticoid corticosteroids for Duchenne muscular dystrophy | Q24242199 | ||
| Skeletal muscle fiber type: influence on contractile and metabolic properties | Q24799445 | ||
| PGC-1alpha: a key regulator of energy metabolism | Q28274239 | ||
| IKK-beta links inflammation to obesity-induced insulin resistance | Q29614285 | ||
| A review of nutrition in Duchenne muscular dystrophy | Q33501842 | ||
| Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures | Q33975979 | ||
| PPARs, Obesity, and Inflammation | Q34003196 | ||
| Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. | Q34994545 | ||
| Therapeutics for Duchenne muscular dystrophy: current approaches and future directions. | Q35607136 | ||
| Taurine and skeletal muscle disorders | Q35678828 | ||
| PGC-1alpha regulates the neuromuscular junction program and ameliorates Duchenne muscular dystrophy. | Q35720854 | ||
| The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity | Q35927748 | ||
| Molecular mechanisms of glutamine action | Q36082609 | ||
| Adaptive and nonadaptive responses to voluntary wheel running by mdx mice | Q36083617 | ||
| Damage and inflammation in muscular dystrophy: potential implications and relationships with autoimmune myositis | Q36285793 | ||
| Creatine monohydrate as a therapeutic aid in muscular dystrophy | Q36420892 | ||
| Muscle damage in mdx (dystrophic) mice: role of calcium and reactive oxygen species. | Q36514267 | ||
| Of bears, frogs, meat, mice and men: complexity of factors affecting skeletal muscle mass and fat. | Q36602855 | ||
| The role of free radicals in the pathophysiology of muscular dystrophy | Q36649415 | ||
| Duchenne muscular dystrophy: focus on pharmaceutical and nutritional interventions. | Q36669820 | ||
| High-fat diets: modeling the metabolic disorders of human obesity in rodents | Q36787703 | ||
| The role of corticosteroids in muscular dystrophy: a critical appraisal | Q36836822 | ||
| Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy | Q36841572 | ||
| IL-6 signalling in exercise and disease | Q36979813 | ||
| Animal models for genetic neuromuscular diseases | Q37059675 | ||
| Implications of cross-talk between tumour necrosis factor and insulin-like growth factor-1 signalling in skeletal muscle. | Q37063632 | ||
| Two-tiered hypotheses for Duchenne muscular dystrophy. | Q37104774 | ||
| Mammalian animal models for Duchenne muscular dystrophy | Q37393140 | ||
| Developing standard procedures for murine and canine efficacy studies of DMD therapeutics: report of two expert workshops on "Pre-clinical testing for Duchenne dystrophy": Washington DC, October 27th-28th 2007 and Zürich, June 30th-July 1st 2008. | Q37396962 | ||
| Dysregulated intracellular signaling and inflammatory gene expression during initial disease onset in Duchenne muscular dystrophy | Q37489327 | ||
| Diagnosis and new treatments in muscular dystrophies | Q37521427 | ||
| Regulation of skeletal muscle physiology and metabolism by peroxisome proliferator-activated receptor delta | Q37608799 | ||
| Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management | Q37640907 | ||
| Molecular treatments in Duchenne muscular dystrophy | Q37740396 | ||
| Examination of 'lipotoxicity' in skeletal muscle of high-fat fed and ob/ob mice | Q38356734 | ||
| Pharmacological activation of PPARbeta/delta stimulates utrophin A expression in skeletal muscle fibers and restores sarcolemmal integrity in mature mdx mice | Q39801012 | ||
| Protein turnover is elevated in muscle of mdx mice in vivo | Q42217671 | ||
| Defective regulation of energy metabolism in mdx-mouse skeletal muscles | Q42494294 | ||
| Components of energy expenditure in the mdx mouse model of Duchenne muscular dystrophy | Q42627877 | ||
| A new chart for weight control in Duchenne muscular dystrophy | Q42993038 | ||
| A growth stimulus is needed for IGF-1 to induce skeletal muscle hypertrophy in vivo | Q43152610 | ||
| Muscle-to-fat interaction: a two-way street? | Q43203178 | ||
| Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice | Q43818941 | ||
| Screening for increased protein thiol oxidation in oxidatively stressed muscle tissue. | Q43994358 | ||
| Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1. | Q44255035 | ||
| Hypertrophic response of Duchenne and limb-girdle muscular dystrophies is associated with activation of Akt pathway | Q44610584 | ||
| Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy | Q44907892 | ||
| Treatments for muscular dystrophy: increased treatment options for Duchenne and related muscular dystropies | Q45878146 | ||
| CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. | Q46571375 | ||
| Nutritional therapy improves function and complements corticosteroid intervention in mdx mice | Q46691988 | ||
| Distinct phenotypes of obesity-prone AKR/J, DBA2J and C57BL/6J mice compared to control strains | Q46757960 | ||
| N-Acetylcysteine ameliorates skeletal muscle pathophysiology in mdx mice | Q46765634 | ||
| Reduced muscle necrosis and long-term benefits in dystrophic mdx mice after cV1q (blockade of TNF) treatment | Q46799394 | ||
| Impaired mitochondrial oxidative phosphorylation in skeletal muscle of the dystrophin-deficient mdx mouse | Q47878704 | ||
| Evaluation of potential synergistic action of a combined treatment with alpha-methyl-prednisolone and taurine on the mdx mouse model of Duchenne muscular dystrophy. | Q48133974 | ||
| High protein diet has beneficial effects in murine muscular dystrophy | Q49178880 | ||
| Fasting increases the extent of muscle necrosis in the mdx mouse. | Q51581266 | ||
| Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. | Q53252919 | ||
| Measurement of sub-membrane [Ca2+] in adult myofibers and cytosolic [Ca2+] in myotubes from normal and mdx mice using the Ca2+ indicator FFP-18. | Q53749439 | ||
| Three mouse models of muscular dystrophy: the natural history of strength and fatigue in dystrophin-, dystrophin/utrophin-, and laminin α2-deficient mice | Q57270383 | ||
| Body composition and energy expenditure in Duchenne muscular dystrophy | Q57992157 | ||
| The mdx mouse skeletal muscle myopathy: II. Contractile properties | Q68025103 | ||
| Electron microscopic and autoradiographic characterization of hindlimb muscle regeneration in the mdx mouse | Q68529448 | ||
| Muscle wasting in muscular dystrophy: Decreased protein synthesis or increased degradation? | Q70244228 | ||
| Does muscular dystrophy affect metabolic rate? A study in mdx mice | Q72364164 | ||
| Pre-clinical screening of drugs using the mdx mouse | Q73851369 | ||
| Running endurance abnormality in mdx mice | Q77707435 | ||
| Cromolyn administration (to block mast cell degranulation) reduces necrosis of dystrophic muscle in mdx mice | Q79783473 | ||
| Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with Etanercept in mdx mice | Q80173431 | ||
| A new way to regulate the NMJ | Q80265198 | ||
| Blockade of TNF in vivo using cV1q antibody reduces contractile dysfunction of skeletal muscle in response to eccentric exercise in dystrophic mdx and normal mice | Q82341401 | ||
| Growing muscle has different sarcolemmal properties from adult muscle: a proposal with scientific and clinical implications: reasons to reassess skeletal muscle molecular dynamics, cellular responses and suitability of experimental models of muscle | Q83888480 | ||
| P304 | page(s) | RRN1276 | |
| P577 | publication date | 2011-11-15 | |
| P1433 | published in | PLOS Currents | Q7119653 |
| P1476 | title | The different impact of a high fat diet on dystrophic mdx and control C57Bl/10 mice | |
| P478 | volume | 3 |
| Q64095325 | A modified diet does not ameliorate muscle pathology in a mouse model for Duchenne muscular dystrophy |
| Q90733726 | Biomarkers for Duchenne muscular dystrophy: myonecrosis, inflammation and oxidative stress |
| Q36467072 | Defects in mitochondrial localization and ATP synthesis in the mdx mouse model of Duchenne muscular dystrophy are not alleviated by PDE5 inhibition |
| Q35106988 | Dystropathology increases energy expenditure and protein turnover in the mdx mouse model of duchenne muscular dystrophy |
| Q58751560 | Integrative effects of dystrophin loss on metabolic function of the mdx mouse |
| Q89531241 | Metabolic reprogramming of fibro/adipogenic progenitors facilitates muscle regeneration |
| Q36302421 | Sarcolipin deletion exacerbates soleus muscle atrophy and weakness in phospholamban overexpressing mice |
| Q48510459 | Utrophin up-regulation by artificial transcription factors induces muscle rescue and impacts the neuromuscular junction in mdx mice. |
Search more.